Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company specialising in the treatment of Central Nervous System (CNS) disorders, and mjn-neuro, a start-up that designs, produces and sells medical devices, have announced the signing of a marketing agreement for mjn-SERAS, a wearable medical device that predicts the risk of suffering an epileptic crisis.

With this agreement, Neuraxpharm increases its offer of comprehensive resources for patients with epilepsy and enters the market of complementary solutions. The agreement with mjn-neuro, a member of CataloniaBio & HealthTech, covers all states belonging to the European Union, as well as the United Kingdom, Norway, Iceland, Liechtenstein and Switzerland.

David Blánquez, CEO and co-founder of mjn-neuro, comments: "This is a great moment in the evolution of mjn-neuro. The agreement signed with Neuraxpharm is an important milestone for our strategy and scalability in the epilepsy market, a sector with great potential. We have a lot in common with Neuraxpharm, we are both companies committed to innovation and digital health as a way to improve the quality of life of people with epilepsy. Therefore, we believe that, together, we can achieve new goals and objectives in the coming years.

mjn-SERAS is a non-invasive medical device with sensors that record the electrical activity of the neck in real time and, thanks to artificial intelligence algorithms, its main function is to give a warning when the risk of epilepsy crisis is high. The device will receive the CE mark for Europe in 2020 from BSI Group and the results of the clinical trial are expected in the second half of 2023. It will be the first wearable device to predict epileptic seizures, giving people time to get to a safe place and helping to prevent accidents and injuries.